Saro Arakelians, PharmD

For pharmacists, understanding the evolving therapeutic landscape is essential—not only to optimize drug selection and dosing but also to counsel patients on complex regimens, manage adverse effects, and monitor for treatment-related toxicities.

Diabetic ketoacidosis poses serious risks for patients with diabetes, requiring urgent treatment to prevent life-threatening complications and ensure recovery.

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective VEGF inhibition.

Though new treatments offer hope, careful monitoring and understanding of risks remain essential for their success.

Breast cancer treatment is highly individualized and based on the stage, hormone receptor status, HER2 expression, and patient-specific factors.

Pharmacists should educate patients about their treatment regimen and potential adverse effects.

Antiviral treatments can accelerate healing and reduce complications.

Treatment options may include treating the anemia with blood transfusions, androgen therapy, thalidomide, and other medications.

Pharmacists can educate and encourage screenings for colon cancer to ensure it is discovered as early as possible.

The management of MDS is primarily targeted at controlling or slowing the disease and preventing future complications as much as possible.

However, early diagnosis still presents challenges and limits treatment options.

Alirocumab (Praluent; Regeneron), is a PCSK9 inhibitor indicated for the treatment of adults with heterozygous familiar hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease.

Pharmacists can provide extra resources for patients, including explanations of the therapy options for the patients, the course of therapy, and what patients can expect.

Pharmacists can play a crucial role in educating patients on the proper storage and administration of evolocumab.

Pharmacists have been shown to contribute to improved adherence rates, therapy optimization, patient safety, and cost-savings.

With gene therapy, anti-tissue factor pathway inhibitors, and RNA interference therapy targeting antithrombin, there are many new options that will be available for the patients impacted by hemophilia.

The CDC recommends RSV vaccination for all adults aged 60 years and older.

Treatment decisions should depend on the patient, their disease, and their disease progression.

Biosimilars are proven to be highly similar to the original products with no clinical meaningful differences.

With wider testing available, diagnosing COVID-19 has become easier and many patients now have access to important treatment options.

Regardless of which of these vaccines patients receive, as long as they receive them according to the prescribed schedules, they can protect themselves and their community against the COVID-19 virus.

Acne is one of the most common conditions, with about 50 million Americans dealing with acne annually.

Even with the current available treatment options, it is important to recognize the importance of masking, particularly for those with immunocompromised conditions.

With the organism’s potential to cause severe symptoms, severe disease, and possible death, it is essential to care for infected individuals promptly and safely.

Treatment options for individuals impacted with PMS can vary and include lifestyle modifications, medication treatments, and herbal products.

According to 2020 data from the CDC, about 14.5% of adults reported having trouble falling asleep most or every day during the 30 days prior to the survey.

RSV can create a problematic infection among children 12 months of age or younger, older adults, and in patients with immunocompromised conditions.

Continuous glucose monitors can significantly improve the lives of patients with diabetes, offering less finger pokes, improved compliance, and easier use methods.

HCV infection is mostly curable and treated with antiviral medications, which can clear the virus from the body.

Approximately every 2.2 minutes, a new diagnosis of lung cancer is registered.